TL;DR
This study investigated the effectiveness of zonisamide for treating infantile spasms (IS) in a large cohort of children, finding it to have favorable tolerability but very limited efficacy, particularly in patients who have already failed first-line treatments like hormonal therapy or vigabatrin. The findings challenge previous smaller studies and suggest zonisamide is best considered for a very specific subset of refractory IS patients.
What Problem Does This Paper Address?
Infantile spasms (IS) are a severe form of epileptic encephalopathy that can lead to significant long-term developmental impairments if not treated effectively. While first-line therapies like vigabatrin and hormonal treatments are successful in about two-thirds of cases, a substantial portion of children develop refractory IS, meaning they don't respond to these initial treatments. For these children, treatment options become limited and often rely on therapies with less robust evidence. Zonisamide has been suggested as a potential option for refractory IS based on a few small studies, but its true efficacy and safety in a larger, real-world population, especially those with treatment-resistant epilepsy, remained unclear. This paper aims to address this gap by evaluating the efficacy and safety of zonisamide in a large, single-center cohort of children with IS, with a particular focus on those with refractory epilepsy.
Methods
The researchers conducted a retrospective cohort study, analyzing data from the electronic medical records of patients who underwent video-EEG at UCLA Mattel Children's Hospital. They identified 87 children diagnosed with infantile spasms who were treated with zonisamide. Key data points collected included dates of birth, IS onset, zonisamide initiation, response to treatment, and most recent follow-up. To assess zonisamide exposure, they meticulously recorded patient weights and daily dosages at each encounter, allowing for the calculation of peak and weighted-average weight-based doses.
Treatment response was defined in two ways:
- Clinical response: Parent-reported resolution of epileptic spasms within three months of starting zonisamide, with no recurrence in the following month.
- Electroclinical response: Clinical response confirmed by overnight video-EEG, showing the absence of both epileptic spasms and hypsarrhythmia.
Adverse events were also documented, focusing on sedation, appetite reduction/weight loss, acidosis, nephrolithiasis, and oligohydrosis. Statistical analyses included summary statistics (median and IQR for continuous variables) and comparisons using the Wilcoxon rank-sum test and Fisher exact test.
Datasets
The study utilized a retrospective dataset derived from the electronic medical records of patients treated at UCLA Mattel Children's Hospital between January 2008 and January 2018. This dataset comprised 87 children with video-EEG confirmed infantile spasms who received zonisamide treatment. No new datasets or benchmarks were introduced.
Key Insights and Ideas
- Refractory IS is a major challenge: The study highlights that a significant majority (90%) of their zonisamide-treated cohort had already failed multiple prior treatments, underscoring the difficulty in managing refractory infantile spasms.
- Zonisamide's limited role in refractory cases: The most striking finding is the very low response rate to zonisamide in patients who had previously failed hormonal therapy or vigabatrin. This directly contradicts the notion that zonisamide is a broadly effective option for refractory IS.
- Early treatment matters: The two patients who achieved electroclinical response were treated with zonisamide as a first-line therapy, suggesting that its efficacy might be significantly higher when used earlier in the treatment course, before other therapies have failed.
- Publication bias is a concern: The authors propose that previous studies showing higher efficacy might be influenced by publication bias, where studies with negative findings (low response rates) are less likely to be published, especially in smaller cohorts.
- Safety profile is favorable: Despite limited efficacy, zonisamide was generally well-tolerated, with no deaths reported and no specific side effects leading to discontinuation. This suggests it might still have a role in specific, carefully selected cases.
Key Results
- Overall Efficacy: Only 5 out of 87 (6%) patients showed a clinical response to zonisamide.
- Electroclinical Efficacy: A mere 2 out of 87 (2%) patients achieved an electroclinical response (clinical response confirmed by video-EEG).
- Refractory Patients: Among the 78 patients who had previously failed hormonal therapy or vigabatrin, the electroclinical response rate was 0%.
- First-Line Patients: In contrast, among the 9 patients treated with zonisamide before hormonal therapy or vigabatrin, the electroclinical response rate was 22% (95% CI: 3, 80%).
- Dosage: Peak weight-based zonisamide dosage averaged 7.1 mg/kg/day, and weighted-average dosage was 5.4 mg/kg/day.
- Adverse Events: Sedation was reported in 10% of patients, and appetite/weight loss in 17%. Metabolic acidosis occurred in 15% of cases. No cases of nephrolithiasis or oligohydrosis were identified.
Limitations and Future Work
The authors acknowledge several limitations:
- Retrospective Design: The study's retrospective nature means data collection was based on existing medical records, which may have limitations in completeness or standardization.
- Selection Bias: The study population was heavily enriched with refractory patients, which may skew the results and limit generalizability to less refractory cases. The decision to use zonisamide was often made late in the treatment course.
- Limited Sample Size for First-Line Use: Only nine patients received zonisamide as a first-line therapy, making it difficult to draw definitive conclusions about its efficacy in this group.
- Underestimation of Adverse Events: The documentation of adverse events in medical records might be incomplete, potentially leading to an underestimation of their true incidence.
Future work suggested includes:
- Prospective Studies: Conducting prospective, ideally randomized, controlled trials to more rigorously evaluate zonisamide's efficacy and safety.
- Targeting Less Refractory Populations: Future studies should ideally focus on larger cohorts of children with less refractory disease or shorter durations of epilepsy to better assess zonisamide's potential.
- Exploring Optimal Dosing and Titration: Further investigation into optimal dosing strategies and titration rates might be warranted, although the current study suggests even higher doses might not overcome the lack of response in refractory cases.
Summary updated